Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction

K Broch, AK Anstensrud, S Woxholt, K Sharma… - Journal of the American …, 2021 - jacc.org
Background Prompt myocardial revascularization with percutaneous coronary intervention
(PCI) reduces infarct size and improves outcomes in patients with ST-segment elevation …

Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial …

O Kleveland, G Kunszt, M Bratlie, T Ueland… - European heart …, 2016 - academic.oup.com
Abstract Aims Interleukin-6 (IL-6) contributes to atherosclerotic plaque destabilization and is
involved in myocardial injury during ischaemia–reperfusion. Interleukin-6 is therefore a …

[HTML][HTML] Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial

C Huse, AK Anstensrud, AE Michelsen, T Ueland… - …, 2022 - thelancet.com
Background We recently showed that interleukin (IL)-6 inhibition by tocilizumab improves
myocardial salvage in ST-elevation myocardial infarction (STEMI). However, the …

Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction

E Holte, O Kleveland, T Ueland, G Kunszt, M Bratlie… - Heart, 2017 - heart.bmj.com
Objective Interleukin-6 (IL-6) is a driver of inflammation and associated endothelial cell
activation in acute coronary syndromes. We evaluated the effect of the IL-6 receptor …

Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation …

AK Anstensrud, S Woxholt, K Sharma, K Broch… - Open …, 2019 - openheart.bmj.com
Introduction Interleukin-6 (IL-6) may be involved in ischaemia-reperfusion injury and
myocardial remodelling after myocardial infarction (MI). We have recently shown that IL-6 …

Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction

O Kleveland, T Ueland, G Kunszt, M Bratlie… - International Journal of …, 2018 - Elsevier
Aim To evaluate the effect of interleukin-6 inhibition with tocilizumab on the cytokine network
in patients with acute non-ST-elevation myocardial infarction (NSTEMI). Methods 117 …

Novel Insights Into the Effects of Interleukin 6 Antagonism in Non–ST‐Segment–Elevation Myocardial Infarction Employing the SOMA scan Proteomics Platform

MJ George, O Kleveland… - Journal of the …, 2020 - Am Heart Assoc
Background Interleukin 6 concentration is associated with myocardial injury, heart failure,
and mortality after myocardial infarction. In the Norwegian tocilizumab non–ST‐segment …

Proteogenomic data integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis

S Prapiadou, L Živković, B Thorand, MJ George… - Circulation, 2024 - Am Heart Assoc
BACKGROUND: Genetic and experimental studies support a causal involvement of IL-6
(interleukin-6) signaling in atheroprogression. Although trials targeting IL-6 signaling are …

Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction

T Ueland, O Kleveland, AE Michelsen, R Wiseth… - Open …, 2018 - openheart.bmj.com
Objective It is unclear if activation of inflammatory pathways regulates proprotein convertase
subtilisin-kexin type 9 (PCSK9) levels. Approach We evaluated (1) the temporal course of …

Serum lipoprotein (a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction

T Ueland, O Kleveland, AE Michelsen, R Wiseth… - International Journal of …, 2019 - Elsevier
Background The IL-6 receptor antagonist tocilizumab has been shown to attenuate the
proatherogenic lipoprotein a [Lp (a)] in rheumatoid arthritis. We evaluated if a single dose of …